- Semaglutide use was associated with an increased long-term risk of nonarteritic anterior ischemic optic neuropathy (NAION) in diabetes patients.
- No increased risk was observed within the first year, but semaglutide users exhibited a significantly heightened risk of NAION from year 2 onward.
- Variations in risk were observed across subgroups such as age, sex, race, comorbidities, and GLP-1 RA medication.
- Exclusive semaglutide use was linked to elevated risk.
- Limitations included the study's retrospective design and reliance on diagnostic codes.
- Further research is needed to continue to explore this association, researchers noted.
Source: JAMA Ophthalmology
